Similar articles

• [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].

  Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Ritz E. Palmer AJ, et al. Dtsch Med Wochenschr. 2004 Jan 2;129(1-2):13-8. doi: 10.1055/s-2004-812656. Dtsch Med Wochenschr. 2004. PMID: 14703575 German.
• [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].

  Palmer AJ, Roze S, Rodby RA, Valentine WJ, Ritz E, Lehnert H. Palmer AJ, et al. Dtsch Med Wochenschr. 2006 Aug 4;131(31-32):1721-6. doi: 10.1055/s-2006-947822. Dtsch Med Wochenschr. 2006. PMID: 16868875 German.
• Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.

  Palmer AJ, Valentine WJ, Ray JA. Palmer AJ, et al. Int J Clin Pract. 2007 Oct;61(10):1626-33. doi: 10.1111/j.1742-1241.2007.01343.x. Int J Clin Pract. 2007. PMID: 17877649 Review.
• [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].

  Frei A, Palmer AJ, Burnier M, Hess B. Frei A, et al. Praxis (Bern 1994). 2006 Mar 15;95(11):401-8. doi: 10.1024/0369-8394.95.11.401. Praxis (Bern 1994). 2006. PMID: 16570646 German.
• Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan.

  Gialama F, Maniadakis N. Gialama F, et al. Vasc Health Risk Manag. 2013;9:575-92. doi: 10.2147/VHRM.S50831. Epub 2013 Oct 7. Vasc Health Risk Manag. 2013. PMID: 24124375 Free PMC article. Review.